^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HPV-16 E6 protein inhibitor

    Related drugs:
    13d
    HPV16 E6 TCR T Cells for Cervical Carcinoma (clinicaltrials.gov)
    P1/2, N=5, Terminated, TCRCure Biopharma Ltd. | N=18 --> 5 | Trial completion date: Aug 2025 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jan 2026; Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HLA-A*02 positive
    |
    cyclophosphamide • fludarabine IV
    14d
    A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=10 --> 7
    Enrollment closed • Enrollment change
    |
    NavDx®
    |
    eseba-vec (HB-200) • HB-201
    3ms
    VERSATILE-003: Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=351, Active, not recruiting, PDS Biotechnology Corp. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Versamune HPV
    4ms
    QUILT-3.100: IBRX-042 In Participants With HPV-Associated Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Sep 2027
    Enrollment closed • Trial primary completion date
    4ms
    VERSATILE-002: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (clinicaltrials.gov)
    P2, N=95, Completed, PDS Biotechnology Corp. | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Versamune HPV
    5ms
    Anisomelic acid promotes proteasomal degradation of HPV16 E6 via E3 ligase recruitment: A mass spectrometry-based interactome study. (PubMed, J Proteomics)
    To our knowledge, this represents the first comprehensive proteomics framework of the HPV16 E6 interactome under small-molecule treatment conditions. These findings support a model in which AA facilitates proteasome-mediated elimination of E6, and the dataset itself provides a timely and valuable resource for HPV biology and therapeutic development.
    Journal
    |
    TP53 (Tumor protein P53) • CDC20 (Cell Division Cycle 20) • TRIP12 (Thyroid Hormone Receptor Interactor 12)
    5ms
    H-200-001: A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (clinicaltrials.gov)
    P1/2, N=198, Completed, Hookipa Biotech GmbH | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
    6ms
    Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Weill Medical College of Cornell University
    New P2 trial
    |
    Versamune HPV
    6ms
    Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Anhui Provincial Hospital
    New trial
    |
    HPV-T
    7ms
    VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov)
    P2, N=35, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jun 2025 | Trial primary completion date: Jun 2025 --> Dec 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    bizalimogene ralaplasmid (VGX-3100)
    7ms
    Reduction of NFX1-123 and HPV 16 E6 and E7 Decreased Telomerase and CENP-F in Cervical Cancer Cell Lines. (PubMed, Cancers (Basel))
    These findings highlight the shared role that NFX1-123 has with HPV 16 oncogenes in driving and maintaining RNA, cell cycle, and carcinogenesis pathways, and specifically regulating hTERT, telomerase, and CENP-F.
    Preclinical • Journal
    |
    TERT (Telomerase Reverse Transcriptase)
    8ms
    A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Oct 2026 | Trial primary completion date: Jul 2025 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Versamune HPV